Загрузка компании
Just reported
Q3 2026 results
From Viatris's results release of 5 ноября 2026 г.; its quarterly report has since been filed.
Revenue
Actual
3,75B $
-0,3 % y/y
-0,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,28 $
Guided
—
No guide given
EPS, adjusted: 0,71 $
Operating income, GAAP
Actual
261,5M $
+46 % y/y
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Viatris is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B $A
NBIXNeurocrine Biosciences, Inc.16,9B $A+
ELANElanco Animal Health Incorporated13,4B $A
KNSAKiniksa Pharmaceuticals International, plc8,2B $A+
LQDALiquidia Corporation5,2B $A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
Полная финансовая отчётность →
Построено по собственной отчётности Viatris Inc., поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
